Abstract
Adult T-cell leukaemia/lymphoma (ATL) is a highly aggressive CD4+ T-cell malignancy caused by human T-cell leukaemia virus type 1. Measles virus (MV) oncolytic therapy has been reported to be efficient in reducing tumour burden in subcutaneous xenograft models of lymphoproliferative disorders such as myeloma, B-cell lymphoma and cutaneous T-cell lymphoma, but its potential to reduce tumour burden in disseminated lymphoproliferative disorders such as ATL remains to be determined. In this study, MV oncolytic therapy was evaluated in the MET-1/NOD/SCID xenograft mouse model of ATL. Treatment with the vaccine-related strain MV-NSE led to a significant reduction in tumour burden. In mice with a high tumour burden, therapy with MV-NSE significantly increased survival beyond any other single treatment tested previously using this model. Interestingly, signs of morbidity (cachexia) in mice treated with MV were not directly associated with tumour burden, but were correlated with the secretion of interleukin-6 by MET-1 cells and host cells. The results suggest that MV therapy could be a promising therapy for generalized lymphoproliferative disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1458-1466 |
| Number of pages | 9 |
| Journal | Journal of General Virology |
| Volume | 92 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2011 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Virology
Cite this
Measles virotherapy in a mouse model of adult T-cell leukaemia/lymphoma. / Parrula, Cecilia; Fernandez, Soledad A.; Zimmerman, Bevin; Lairmore, Michael Dale; Niewiesk, Stefan.
In: Journal of General Virology, Vol. 92, No. 6, 06.2011, p. 1458-1466.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Measles virotherapy in a mouse model of adult T-cell leukaemia/lymphoma
AU - Parrula, Cecilia
AU - Fernandez, Soledad A.
AU - Zimmerman, Bevin
AU - Lairmore, Michael Dale
AU - Niewiesk, Stefan
PY - 2011/6
Y1 - 2011/6
N2 - Adult T-cell leukaemia/lymphoma (ATL) is a highly aggressive CD4+ T-cell malignancy caused by human T-cell leukaemia virus type 1. Measles virus (MV) oncolytic therapy has been reported to be efficient in reducing tumour burden in subcutaneous xenograft models of lymphoproliferative disorders such as myeloma, B-cell lymphoma and cutaneous T-cell lymphoma, but its potential to reduce tumour burden in disseminated lymphoproliferative disorders such as ATL remains to be determined. In this study, MV oncolytic therapy was evaluated in the MET-1/NOD/SCID xenograft mouse model of ATL. Treatment with the vaccine-related strain MV-NSE led to a significant reduction in tumour burden. In mice with a high tumour burden, therapy with MV-NSE significantly increased survival beyond any other single treatment tested previously using this model. Interestingly, signs of morbidity (cachexia) in mice treated with MV were not directly associated with tumour burden, but were correlated with the secretion of interleukin-6 by MET-1 cells and host cells. The results suggest that MV therapy could be a promising therapy for generalized lymphoproliferative disease.
AB - Adult T-cell leukaemia/lymphoma (ATL) is a highly aggressive CD4+ T-cell malignancy caused by human T-cell leukaemia virus type 1. Measles virus (MV) oncolytic therapy has been reported to be efficient in reducing tumour burden in subcutaneous xenograft models of lymphoproliferative disorders such as myeloma, B-cell lymphoma and cutaneous T-cell lymphoma, but its potential to reduce tumour burden in disseminated lymphoproliferative disorders such as ATL remains to be determined. In this study, MV oncolytic therapy was evaluated in the MET-1/NOD/SCID xenograft mouse model of ATL. Treatment with the vaccine-related strain MV-NSE led to a significant reduction in tumour burden. In mice with a high tumour burden, therapy with MV-NSE significantly increased survival beyond any other single treatment tested previously using this model. Interestingly, signs of morbidity (cachexia) in mice treated with MV were not directly associated with tumour burden, but were correlated with the secretion of interleukin-6 by MET-1 cells and host cells. The results suggest that MV therapy could be a promising therapy for generalized lymphoproliferative disease.
UR - http://www.scopus.com/inward/record.url?scp=79956326731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79956326731&partnerID=8YFLogxK
U2 - 10.1099/vir.0.028910-0
DO - 10.1099/vir.0.028910-0
M3 - Article
C2 - 21325484
AN - SCOPUS:79956326731
VL - 92
SP - 1458
EP - 1466
JO - Journal of General Virology
JF - Journal of General Virology
SN - 0022-1317
IS - 6
ER -